Background/Aims: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm. Tyrosine kinase inhibitors (TKIs) are commonly used to treat CML; however, drug resistance of CML cells to TKIs has limited their clinical application. Shikonin, a traditional Chinese herb, has long been used to treat leukemia in China, but the roles and related molecular mechanisms of shikonin treatment in CML remain unclear. Here, we aimed to evaluate the effects of shikonin on the proliferation, apoptosis, and migration of K562 cells, a CML cell line. Methods: Firstly, K562 cell proliferation and apoptosis were tested by CCK8 assay and flow cytometry with Annexin V-FITC/PI staining. Cell migration was measured by Transwell migration assay. In addition, western blot was performed to determine the proteins (PI3K, Bax, Bcl-2, cleaved caspase-3, PTEN, p-AKT, AKT, CXCR4, SDF-1, CD44) involved in the mechanism of action of shikonin. Finally, neutrophils from peripheral blood of CML patients were obtained, and cell proliferation and apoptosis were tested by CCK8 assay and flow cytometry. Results: Shikonin reduced the proliferation of K562 cells in a time-and dose-dependent manner and promoted the apoptosis of K562 cells. Moreover, shikonin increased the PTEN level and inactivated the PI3K/AKT signaling pathway, subsequently upregulating BAX in K562 cells. In addition, shikonin could block K562 cell migration via the CXCR4/SDF-1 axis. Finally, shikonin significantly inhibited the proliferation and promoted the apoptosis of neutrophils from CML
Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm induced by the BCR-ABL1 (breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1) fusion gene with an incidence of 1-2 cases per 100, 000 people and accounts for 15% of newly diagnosed cases of leukemia in adults [1] . Tyrosine kinase inhibitors (TKIs) that target BCR-ABL1 are the standard treatment for CML. Although TKIs are extensively used to treat CML patients, serious drug-drug interactions and emerging resistance of CML cells to TKIs through multiple mechanisms have limited their clinical application [2] . Hence, new therapeutic strategies with less toxicity and higher efficacy are urgently required, especially for relapsing and chemo-resistant CML patients.
Lithospermum erythrorhizon, referred to as "Zicao" in Chinese, is a plant that is used as a "heat-clearing and blood-cooling" medicine. The extracts of Zicao root have been used in traditional Chinese medicine as a cancer treatment for many years [3] . Shikonin (C 16 H 16 O 5 ) is a naturally occurring naphthoquinone compound in the root of herb Lithospermum erythrorhizon and shows pleiotropic effects on some diseases, including anti-tumor, antiischemic, anti-inflammatory, and anti-bacterial effects as well as acceleration of tissue granulation proliferation [4] . Shikonin also inhibited cells viability and induced apoptosis of Cholangiocarcinoma cells, effects enhanced by TRAIL treatment via ROS mediated JNK signalling pathways [5] . Previous reports suggested that shikonin could induce oxidative activities and apoptotic effects in HL-60 cells [6] . In addition, shikonin could exert antileukemic activity through inhibiting the c-MYC and related ERK/JNK/MAPK pathways in U937 [7] . Moreover, shikonin, as a generator of ROS, could induce oxidative injury in apoptotic signaling cascades and may be a promising agent for the treatment of CML [8] .
Phosphatases and tensin homolog (PTEN) plays an important role in mature organisms as a tumor suppressor. PTEN gene inactivation by mutation or deletion is common in pediatric T-cell acute lymphoblastic leukemia (T-ALL) [9] . The major substrate of PTEN is phosphatidylinositol-3, 4, 5-triphosphate (PIP3), which is produced by the action of phosphoinositide-3-kinase (PI3K) [10] . The PI3K/AKT signaling pathway plays an important role in the development of resistance to carcinoma therapy, and inhibition of the PI3K/AKT signaling pathway may suppress cancer cell growth and induce apoptosis in various cancers [11] [12] [13] . PTEN is the main negative regulator of the PI3K/AKT signaling pathway and is implicated in regulating proliferation and survival of T-cell progenitors [14] .
Although the efficacy of shikonin has been reported, its precise anti-CML role and underlying molecular mechanism remain to be elucidated. Here, we evaluated the therapeutic efficacy of shikonin in K562 cells (CML cell line) and neutrophils from CML patients. Understanding the efficacy and mode of action of shikonin will provide a foundation for its potential use in clinical settings.
Materials and Methods

Reagents
Shikonin was purchased from Sigma Chemical Company (St. Louis, MO, USA) and dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich, St. Louis, MO, USA). Potassium bisperoxo (1, 10-phenanthroline) oxovanadate (BPV) (Sigma-Aldrich), a PTEN inhibitor, was used at 1 µM in DMSO. Wortmanin (SigmaAldrich), a specific PI3K inhibitor, was used at 50 nM in DMSO.
Cell culture and primary samples
The leukemia cell lines K562 (chronic myelocytic leukemia), KU812 (basophilic leukemic cells in human peripheral blood), and MEG-01 (human megakaryocyte leukemia cells) were grown in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum (FBS) and treated with shikonin at the indicated concentrations.
Neutrophils from peripheral blood of CML patients were obtained with a human peripheral blood neutrophil separation solution kit (Haoyang, Tianjin, China) as follows: 5 mL of neutrophil separation solution I was added to a 15-mL conical tube. Human peripheral blood was overlaid on the neutrophil separation solution I and centrifuged continuously for 30 min at 500 g at 25 °C. After centrifugation, two cell layers appeared in the centrifuge tube; the upper-layer cells were mononuclear cells, and the lowerlayer cells were neutrophils. The neutrophils were collected, identified with a blood film (Fig. 8I, 8J ), grown in RPMI 1640 supplemented with 20% FBS, and treated with shikonin. Control cells were treated with 0.1% DMSO.
Cell viability assay
Cell viability was assessed by the CCK8 colorimetric assay (Beyotime, Hangzhou, China) as previously described [15] . Briefly, cells were plated in 96-well plates (2×10 3 cells/well) and incubated at 37 °C with 5% CO 2 for 24 h, 48 h, and 72 h, and the absorbance was recorded at 450 nm using a micro-plate reader (BioTek, Winooski, VT, USA). The results were presented as viability rates. Cell viability was calculated according to the following formula: Cell viability (%) = (OD treatment-OD blank)/(OD control-OD blank).
Apoptosis assay
Cell apoptosis was detected using the Annexin V-FITC/PI Apoptosis Detection Kit (Beyotime, Haimen, China) following the manufacturer's instructions after drug treatment. Briefly, cells at a density of 5×10 5 cells/mL were resuspended and mixed in 500 μL binding buffer with 5 μL Annexin V-FITC and 5 μL propidium iodide (PI). After incubation for 15 min, cell apoptosis was detected by flow cytometry (NovoCyte, ACEA Biosciences, San Diego, CA, USA).
Western blot
Cells were lysed with RIPA lysis buffer (Beyotime) to extract the total protein. Then, the concentration of total protein was quantitated by a bicinchoninic acid (BCA) protein assay kit (Beyotime). Equal amounts of protein were separated by SDS-polyacrylamide gel electrophoresis (PAGE) and transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA, USA). After being blocked with 5% non-fat milk for 1 h, the membranes were probed with specific primary antibodies against PI3K, Bax, Bcl-2, cleaved caspase-3, PTEN, p-AKT, AKT, CXCR4, SDF-1, CD44, GAPDH, and actin (1:1, 000, Cell Signaling Technology, Danvers, MA, USA) at 4 °C overnight and subsequently incubated with the corresponding secondary antibodies (1:5, 000, Beyotime) for 1 h at room temperature. An enhanced chemiluminescence (ECL) solution (Qihai Biotec, Shanghai, China) was used to visualize the target bands, and the Gel-Pro Analyzer software (Media Cybernetics, Bethesda, MD, USA) was employed to measure relative band intensities. GAPDH or actin served as an internal control, respectively.
Reverse transcription-PCR (RT-PCR) assay
K562 cells were cultured with shikonin at 10, 20, or 40 μM for 24 h, while the control cells were treated with 0.1% DMSO. After shikonin incubation, the mRNA from K562 cells was extracted (MagnaPure LC RNA Isolation Kit; Roche Applied Science, Penzberg, Germany) and reverse transcribed into cDNA with the Transcription High Fidelity cDNA Synthesis Kit (Roche Applied Science) following the corresponding manufacturer's instructions. With template DNA prepared, the parameters of amplification reaction were as follows: 3 min at 95 °C, followed by 40 cycles for 10 sec at 95 °C, and 30 sec at 60 °C. The primer pairs used are listed in Table 1 .
Transwell migration assay
Cell migration was determined using the Transwell migration assay (Corning Life Sciences, Acton, MA, USA), according to the manufacturer's instructions and as previously described [16] . Briefly, K562 cells 
Statistics
Statistical analysis was performed using GraphPad Prism v. 5.0 software (GraphPad Software, Inc., La Jolla, CA, USA). Data are expressed as means ± standard deviation (SD). All data presented represent results from at least three independent experiments. One-way analysis of variance followed by Tukey's multiple comparison test was used to compare differences between groups. Statistical significance was defined as P < 0.05.
Results
Shikonin inhibited the proliferation of CML cell lines
To examine whether shikonin could affect the growth of leukemia cells, we first performed CCK8 assays using K562, a typical CML cell line. Cultured K562 cells were treated with a series of shikonin concentrations from 0 to 40 μM for 24 h, and then cell viability was measured by CCK8 assay. As shown in Fig. 1A , shikonin significantly reduced viability of K562 cells in a dose-dependent manner. The IC 50 values of shikonin for K562 cells was 22.53 μM (Fig. 1A) . Shikonin also significantly inhibited the growth of K562 cells in a time-dependent manner (for 24 h, 48 h, and 72 h) (Fig.  1B) . To further confirm the inhibition by shikonin specifically in CML cells, other leukemia cell lines, including KU812 (basophilic leukemic cells in human peripheral blood) and MEG-01 (human megakaryocyte leukemia cells) were tested in the same manner. Interestingly, shikonin inhibited the growth of both KU812 (Fig. 1C) and MEG-01 cell lines in a dose-dependent manner (Fig. 1D) ; therefore, K562, KU812, and MEG-01 are all sensitive to shikonin-induced cytotoxicity. Taken together, these results suggested that shikonin reduced the viability of CML cell lines.
Shikonin induced the apoptosis of K562 cells
To further examine whether shikonin affects the survival of K562 cells, we first performed flow cytometry assays. K562 cells were treated with 10, 20, or 40 μM shikonin for 24 h, and then the cells were stained with Annexin-V and PI and analyzed by flow cytometry assays. As shown in Fig. 2A -E, compared with (Fig. 3B,  3E ), whereas levels of proapoptosis proteins cleaved caspase-3 and Bax were significantly increased after shikonin treatment (Fig.  3A, 3C , and 3D), compared with those of the control group. Taken together, these results strongly suggested that shikonin promoted the apoptosis of K562 cells.
Shikonin enhanced PTEN expression and inactivated the PI3K/ AKT signaling pathway in K562 cells
As PTEN is an important tumor suppressor, we next examined whether shikonin promoted the apoptosis of K562 cells through PTEN/ PI3K/AKT pathways. Interestingly, as shown in Fig. 4A and 4B, western blot results revealed a significant elevation of PTEN protein level after shikonin treatment (20 μM and 40 μM) of K562 cells, whereas the PI3K and p-AKT/AKT levels were significantly decreased by shikonin treatment (Fig.  4C, 4D, and 4E) . The mRNA expression levels of the PTEN/PI3K/AKT signaling pathway were also detected. The results showed that the mRNA level of PTEN was significantly increased after shikonin treatment (Fig. 4F) , while mRNA levels of PI3K and AKT were significantly decreased in (Fig. 4G, 4H ). Taken together, these results suggested that shikonin enhanced PTEN expression and inactivated the PI3K/AKT signaling pathway in K562 cells at the mRNA level, which may mediate the shikonin-induced apoptosis of K562 cells.
PTEN/PI3K/AKT signaling pathway mediated shikonin-induced apoptosis of K562 cells
To further confirm the detailed roles of the PTEN/PI3K/AKT signaling pathway in the shikonin-induced effect on K562 cells, we used specific drug inhibitors to block this pathway. As shown in Fig. 5A , western blots indeed revealed that BPV (a specific inhibitor of PTEN) could block the increase of PTEN and Bax (Fig. 5A , 5B, and 5D) as well as the decrease of p-AKT/AKT in K562 cells treated with shikonin (Fig. 5A, 5C ). In contrast, following treatment with shikonin, wortmanin, an inhibitor of PI3 kinase, decreased the p-AKT/AKT level in K562 cells (Fig. 5A, 5C ). Moreover, BPV significantly blocked shikonin-induced apoptosis of K562 cells, whereas wortmanin significantly enhanced shikonin-induced apoptosis of K562 cells (Fig. 6) . These results provided additional evidence to support the mediation of shikonininduced effects (inhibition of cell proliferation and promotion of apoptosis) on K562 cells by the PTEN/PI3K/AKT signaling pathway.
Shikonin blocked CML cell migration via the CXCR4/SDF-1 axis in K562 cells
CML patients in accelerated phase or blast crisis can develop extramedullary involvement, including hepatosplenomegaly, enlarged lymph nodes, chloromas, etc [17] .. Therefore, inhibition of the migration of K562 cells is of great importance. To examine whether shikonin could affect the migration of K562 cells, Transwell migration assay was conducted. Compared with that of control cells, the migration of K562 was significantly blocked after shikonin treatment (Fig.  7F) . Additionally, the CXCR4/ SDF-1 axis is involved in tumor progression, angiogenesis, metastasis, and survival [18] . Western blot revealed that the protein levels of CXCR-4, SDF-1, and CD44 in K562 cells were significantly decreased after shikonin treatment (Fig. 7A-E) . These results provided evidence that shikonin blocks migration of K562 cells via inhibition of the CXCR4/SDF-1 axis.
Shikonin inhibited the proliferation and promoted the apoptosis of neutrophils from CML patients
In order to study the therapeutic effect of shikonin in CML patients, peripheral blood (PB) neutrophils from 12 different CML patients were isolated and treated with shikonin. We found that shikonin significantly reduced the cell viability of PB neutrophils (Fig. 8A, 8B ) from CML patients compared with that of healthy neutrophils. Moreover, shikonin significantly induced the apoptosis of PB neutrophils (Fig. 8C-H ) from CML patients compared with that of healthy cells. Taken together, these results suggest that shikonin inhibited the proliferation and 
promoted the apoptosis of PB neutrophils from CML patients, which implies that shikonin is an extremely efficient drug for CML treatment.
Discussion
In this study, we found that shikonin has strong potential therapeutic efficacy in treating CML, both in the CML cell lines and CML patients. Meanwhile, shikonin not only inhibited proliferation and induced apoptosis but also inhibited the migration of K562 cells via the CXCR4/SDF-1 axis. Interestingly, we found that shikonin increased PTEN expression significantly and then inactivated the PI3K/AKT signaling pathway, which is a novel mechanism of shikonin. Therefore, this study revealed a novel pathway, PTEN/PI3K/AKT, by which shikonin exerts therapeutic effects on leukemia.
To counter the emerging resistance of CML cells to TKIs, innovative approaches that are more effective and less toxic are needed. As a major component of Zicao, shikonin exhibits anti-tumor activity [4, 19] and has been reported to be less cytotoxic [20] [21] [22] [23] and circumvent drug resistance [24] of various tumor cell lines. In the present study, we tested the effects of shikonin on K562 cells. Consistent with a previous study [25] , our results also showed that shikonin suppressed the proliferation of K562 cells in a dose-dependent and timedependent manner (Fig. 1 ). In addition, we found that shikonin exerts an anti-CML effect not only though proliferation inhibition but also through apoptosis induction and migration inhibition (Fig. 2, 7) .
Previous studies have shown that shikonin induced the apoptosis of acute myeloid leukemia cells and K562 cells through oxidative stress and mitochondria injury. Consistent with previous studies [8] , we confirmed that shikonin significantly induced the apoptosis of K562 cells based on flow cytometry with Annexin V-FITC/PI staining (Fig. 2) . Furthermore, the antitumor activities of shikonin are mediated through downregulation of anti-apoptotic proteins including Bcl-2 and Bcl-xL and induce caspase activation [26] [27] [28] . Bax migrates to the mitochondrial membrane and inhibits the action of Bcl-2, causing damage to the mitochondrial membrane that in turn releases cytochrome-c, which leads to apoptosis by the activation of caspase-3 and caspase-7 [29] . In our study, western blotting analysis indicated that shikonin treatment resulted in decreased expression of Bcl-2 and increased expression of Bax and cleaved caspase-3 in K562 cells. Thus, these results supported the enhanced apoptosis of K562 cells by shikonin treatment due to the activation of mitochondrial apoptotic pathways.
PTEN is an essential tumor suppressor that antagonizes the PI3K/AKT anti-apoptotic pathway [30, 31] . Thus, PTEN could affect cell growth, proliferation, and survival through counteracting PI3K and downregulating the PI3K/AKT signaling pathway [32] . It has previously been demonstrated that the PTEN/PIK3/AKT pathways are involved in tumorigenesis [31, 33] . Overexpression of PTEN could suppresses leukemia stem cells and induce cell-cycle arrest of CML cells. Moreover, PTEN delays the development of CML, prolonging the survival of leukemia mouse models [34] . Loss of PTEN protein and subsequent p-Akt activation in CML could increase the side population phenotype, which is responsible for the persistence of many solid tumors through ATP-binding cassette sub-family G member 2 (ABCG2) [35] . Overexpression of the PTEN gene inhibits K562 cell proliferation and promotes cell apoptosis via downregulation of the PI3K/Akt pathway [36] . However, in high BCR-ABL-expressing cells, although downregulation of PTEN increases AKT activity, the cell-cycle inhibitor p21 , which is associated with AKT, is PI3K independent [37] . BCR-ABL promotes PTEN downregulation through a MEK-dependent pathway in CML [38] . Furthermore, nuclearcytoplasmic shuttling of PTEN is crucial for its proper tumor suppressive function, and BCR-ABL could disrupt this shuttling of PTEN in CML through aberrant PML/HAUSP crosstalk [39] . In addition, inhibition of the PI3K-Akt pathway promotes Bax translocation to mitochondria, leading to apoptosis [40] . Inhibited RLIP76 expression can transactivate phosphorylation of PI3K-Akt signaling and result in apoptosis [41] . We next tested the functional roles of the potential signaling pathway in shikonin-induced apoptosis. We found that shikonin increased PTEN expression significantly and in turn decreased PI3K and p-AKT/AKT levels by western blot (Fig. 4A-E) . The mRNA level of PTEN was significantly increased (Fig. 4F) , while mRNA levels of PI3K and AKT were significantly decreased in K562 cells after shikonin treatment (Fig. 4G, 4H ). Based on this cumulative evidence, we suggested that shikonin induced apoptosis and inhibited proliferation of K562 cells through the PTEN/PI3K/AKT pathway. Furthermore, in this study, we found that PTEN inhibitor BPV blocked the shikonin-induced apoptosis, whereas PI3K inhibitor wortmanin enhanced the shikonin-induced apoptosis of K562 cells treated with shikonin (Fig. 5, 6 ). These results strongly implied that the shikonininduced apoptosis of K562 cells occurred through enhancement of PTEN and inhibition of the PI3K/AKT signaling pathways and may provide a novel tool for treatment of CML.
CXCR4 (chemokine C-X-C motif receptor 4), a chemokine G protein-coupled receptor [42] , is elevated in a variety of cancers including CML [43, 44] . CXCR4 overexpression could affect tumor growth, invasion, angiogenesis, metastasis, relapse, and therapeutic resistance [45] . SDF-1, also known as CXCL12 (chemokine C-X-C motif ligand 12), is a stromal cell-derived factor 1, which is the sole ligand of CXCR4 and a homeostatic chemokine, overexpressed in many human cancers [45, 46] . Chemotaxis driven by CXCR4 and SDF-1 interactions has been shown to control various biological functions including cell adhesion, migration, and invasion [47] . Moreover, treatment with AMD3100, a selective CXCR4 antagonist, resulted in increased tumor apoptosis and knockdown of SDF-1, reducing cell proliferation and tumor growth [48] . In both murine and human prostate cancer cells, the PTEN loss-activated PI3K/ Akt pathway induces CXCL12/CXCR4 expression, and the Akt1-induced CXCR4 expression affects cellular invasion and tumor growth [49] . The CD44 hyaluronic acid receptor is involved in homing of leukemic cells. Crosstalk existing between the CXCR4/SDF-1 axis and CD44 in normal hematopoietic cells can block acute myeloid leukemia cell homing [50] . In this study, we found that shikonin treatment decreased the expression of CXCR4, SDF-1, and CD44. Furthermore, K562 cell migration was inhibited by shikonin treatment (Fig. 7) . These results indicated that shikonin affects migration of K562 cells via the CXCR4/SDF-1 axis and may involve the PTEN/PI3K/AKT pathway. The findings of this study suggest a novel therapeutic approach for CML.
Since the previous studies of shikonin were focused on cell lines [6] [7] [8] 51] , to investigate the effects of shikonin on CML patients, PB neutrophils from 12 different CML patients were collected and treated with shikonin. PB neutrophils from 12 healthy people were employed as a control. We found that shikonin could also inhibit the proliferation and induce the apoptosis of PB neutrophils from CML patients. These results implied that shikonin has very promising clinical potential for treatment of CML patients. Moreover, shikonin did not affect proliferation and apoptosis of PB neutrophils from healthy people, which suggested that shikonin is a safe medication with few side effects for future clinical use.
In summary, the present study demonstrated that shikonin could inhibit the proliferation and induce the apoptosis of K562 cells and PB neutrophils from CML patients, which is mediated by the PTEN/PI3K/AKT signaling pathway. In addition, shikonin could block K562 cell migration via the CXCR4/SDF-1 axis. Our results revealed the novel effects of shikonin in leukemia therapy and elucidated the detailed mechanisms involving PTEN/PI3K/AKT.
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